General Surgery Department, Tianjin Medical University General Hospital
Welcome,         Profile    Billing    Logout  
 13 Trials 
9 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Jie
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes

Recruiting
3
424
RoW
Victoza®., Metformin Hydrochloride, TQZ2451
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Type 2 Diabetes
12/21
12/21
NCT06198764: A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection

Recruiting
3
80
RoW
Colistimethate sodium for injection, Meropenem for Injection, Coly Mycin M Injectable Product
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Mental Health Issue
03/26
03/26
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in Japan (based on MATINEE trial) for COPD
Active, not recruiting
3
806
Europe, Canada, Japan, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD
Pulmonary Disease, Chronic Obstructive
08/24
08/24
NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment

Recruiting
3
2100
Europe, Canada, Japan, US, RoW
Rimegepant/BHV3000, Matching placebo
Pfizer
Pediatric Migraine
01/29
01/29
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Completed
2
250
RoW
GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table
Sunshine Lake Pharma Co., Ltd.
Chronic HBV Infection
06/22
09/23
TRIPHY, NCT06480890: Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients

Recruiting
N/A
359
RoW
Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
10/25
10/25

Download Options